Long-term kidney transplant outcomes in patients receiving oil-based or microemulsion formulations of cyclosporine
In the last 20 years long-term experience with cyclosporine use in kidney transplantation has increased, allowing a more precise identification of its benefits. We performed a retrospective analysis of 1619 kidney transplants that received cyclosporine-based immunosuppressive therapy. Patients were...
Gespeichert in:
| Veröffentlicht in: | Transplantation proceedings 2004-03, Vol.36 (2), p.S74-S79 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S79 |
|---|---|
| container_issue | 2 |
| container_start_page | S74 |
| container_title | Transplantation proceedings |
| container_volume | 36 |
| creator | Medina-Pestana, J.O Felipe, C.R Park, S.I Machado, P.G.P Garcia, R Spinelli, G Silva, L.A Santos, C.F Tedesco-Silva, H |
| description | In the last 20 years long-term experience with cyclosporine use in kidney transplantation has increased, allowing a more precise identification of its benefits.
We performed a retrospective analysis of 1619 kidney transplants that received cyclosporine-based immunosuppressive therapy. Patients were divided into three groups (1) oil-based cyclosporine (SIM) with trough monitoring (GI,
n = 617); (2) microemulsion formulation (NEO) with trough monitoring (GII,
n = 962); and (3) NEO with C2 monitoring (GIII,
n = 40). Information was obtained on transplant demography; adjunctive immunosuppressive agent; living (LD) versus cadaveric (CAD) recipients; delayed graft function; any treated acute rejection; graft function at 3, 6, and 12 months, patient and graft survival, as well as causes of graft loss and death.
At 15 years follow-up, patient and graft survival were 67.5% and 41.6%, being superior, among LD versus CAD recipients (patient: 78.7% vs 57.7%,
P < .001; graft: 56.4% vs 30.5%,
P < .001). In LD (54% vs 32%,
P < .001) and CAD (69% vs 55%,
P < .001) NEO reduced the incidence of AR and improved 8-year patient (LD: 81.8% vs 94.7%; CAD: 66.4 vs 79.9%,
P < .01) and graft survival (LD: 58.3 vs. 80%; CAD: 40.2% vs. 59.5%,
P < .01), compared to SIM. Overall 8-year graft survival was inferior among patients with increased 1-year creatinine values (≤1.5, 1.6–2.5 and >2.5 mg/dL) level (74% vs 63.9% vs 22.4%,
P < .001) or change in Cr (≤0.1, 0.2–0.4, >0.5 mg/dL) level (73.1% vs 61.9% vs 37.2%,
P < .001). In patients at the same level of graft function, those receiving NEO showed superior 8-year patient and graft survival compared with SIM.
Compared to SIM, NEO reduced the incidence of acute rejection and produced superior long-term patient and graft survival. |
| doi_str_mv | 10.1016/j.transproceed.2004.01.088 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71768514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134504001083</els_id><sourcerecordid>71768514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-5b68f6cd6df159c40326986454b26a1526761707fccfe1d67e2376f9bf9253da3</originalsourceid><addsrcrecordid>eNqNkM2O1DAQhC0EYoeFV0AWB24JbjtxMtzQ8iuNxAXOVmK3Vx4Se7Cdlebt6dWMEEdObququlUfY29AtCBAvzu2NU-xnHKyiK6VQnStgFaM4xO2g3FQjdRSPWU7EqAB1fU37EUpR0F_2ann7AZ6UhTAjuVDivdNxbzyX8FFPPPL7mWKlaet2rRi4SHy01QDxlp4RovhIcR7nsLSzFNBx1Pma7A54botJaTIfco0UiTFwpPn9myXVE4ph4gv2TM_LQVfXd9b9vPzpx93X5vD9y_f7j4cGqsGXZt-1qPX1mnnod_bTiip96Pu-m6WeoJe6kHDIAZvrUdwekBJOb-f_V72yk3qlr297CVQvzcs1ayhWFyoGqatmAEGPfbQkfH9xUgNSsnozSmHdcpnA8I8EjdH8y9x80jcCDBEnMKvr1e2eSXtb_SKmAwfLwakrg8BsymWSFp0gVBW41L4nzt_AO2lnB8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71768514</pqid></control><display><type>article</type><title>Long-term kidney transplant outcomes in patients receiving oil-based or microemulsion formulations of cyclosporine</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Medina-Pestana, J.O ; Felipe, C.R ; Park, S.I ; Machado, P.G.P ; Garcia, R ; Spinelli, G ; Silva, L.A ; Santos, C.F ; Tedesco-Silva, H</creator><creatorcontrib>Medina-Pestana, J.O ; Felipe, C.R ; Park, S.I ; Machado, P.G.P ; Garcia, R ; Spinelli, G ; Silva, L.A ; Santos, C.F ; Tedesco-Silva, H</creatorcontrib><description><![CDATA[In the last 20 years long-term experience with cyclosporine use in kidney transplantation has increased, allowing a more precise identification of its benefits.
We performed a retrospective analysis of 1619 kidney transplants that received cyclosporine-based immunosuppressive therapy. Patients were divided into three groups (1) oil-based cyclosporine (SIM) with trough monitoring (GI,
n = 617); (2) microemulsion formulation (NEO) with trough monitoring (GII,
n = 962); and (3) NEO with C2 monitoring (GIII,
n = 40). Information was obtained on transplant demography; adjunctive immunosuppressive agent; living (LD) versus cadaveric (CAD) recipients; delayed graft function; any treated acute rejection; graft function at 3, 6, and 12 months, patient and graft survival, as well as causes of graft loss and death.
At 15 years follow-up, patient and graft survival were 67.5% and 41.6%, being superior, among LD versus CAD recipients (patient: 78.7% vs 57.7%,
P < .001; graft: 56.4% vs 30.5%,
P < .001). In LD (54% vs 32%,
P < .001) and CAD (69% vs 55%,
P < .001) NEO reduced the incidence of AR and improved 8-year patient (LD: 81.8% vs 94.7%; CAD: 66.4 vs 79.9%,
P < .01) and graft survival (LD: 58.3 vs. 80%; CAD: 40.2% vs. 59.5%,
P < .01), compared to SIM. Overall 8-year graft survival was inferior among patients with increased 1-year creatinine values (≤1.5, 1.6–2.5 and >2.5 mg/dL) level (74% vs 63.9% vs 22.4%,
P < .001) or change in Cr (≤0.1, 0.2–0.4, >0.5 mg/dL) level (73.1% vs 61.9% vs 37.2%,
P < .001). In patients at the same level of graft function, those receiving NEO showed superior 8-year patient and graft survival compared with SIM.
Compared to SIM, NEO reduced the incidence of acute rejection and produced superior long-term patient and graft survival.]]></description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2004.01.088</identifier><identifier>PMID: 15041311</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Chemistry, Pharmaceutical ; Cyclosporine - administration & dosage ; Cyclosporine - therapeutic use ; Drug Therapy, Combination ; Emulsions ; Female ; Graft Survival - drug effects ; Graft Survival - immunology ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - therapeutic use ; Kidney Failure, Chronic - etiology ; Kidney Failure, Chronic - surgery ; Kidney Transplantation - immunology ; Male ; Retrospective Studies ; Time Factors ; Treatment Outcome</subject><ispartof>Transplantation proceedings, 2004-03, Vol.36 (2), p.S74-S79</ispartof><rights>2004 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c376t-5b68f6cd6df159c40326986454b26a1526761707fccfe1d67e2376f9bf9253da3</citedby><cites>FETCH-LOGICAL-c376t-5b68f6cd6df159c40326986454b26a1526761707fccfe1d67e2376f9bf9253da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transproceed.2004.01.088$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15041311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Medina-Pestana, J.O</creatorcontrib><creatorcontrib>Felipe, C.R</creatorcontrib><creatorcontrib>Park, S.I</creatorcontrib><creatorcontrib>Machado, P.G.P</creatorcontrib><creatorcontrib>Garcia, R</creatorcontrib><creatorcontrib>Spinelli, G</creatorcontrib><creatorcontrib>Silva, L.A</creatorcontrib><creatorcontrib>Santos, C.F</creatorcontrib><creatorcontrib>Tedesco-Silva, H</creatorcontrib><title>Long-term kidney transplant outcomes in patients receiving oil-based or microemulsion formulations of cyclosporine</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description><![CDATA[In the last 20 years long-term experience with cyclosporine use in kidney transplantation has increased, allowing a more precise identification of its benefits.
We performed a retrospective analysis of 1619 kidney transplants that received cyclosporine-based immunosuppressive therapy. Patients were divided into three groups (1) oil-based cyclosporine (SIM) with trough monitoring (GI,
n = 617); (2) microemulsion formulation (NEO) with trough monitoring (GII,
n = 962); and (3) NEO with C2 monitoring (GIII,
n = 40). Information was obtained on transplant demography; adjunctive immunosuppressive agent; living (LD) versus cadaveric (CAD) recipients; delayed graft function; any treated acute rejection; graft function at 3, 6, and 12 months, patient and graft survival, as well as causes of graft loss and death.
At 15 years follow-up, patient and graft survival were 67.5% and 41.6%, being superior, among LD versus CAD recipients (patient: 78.7% vs 57.7%,
P < .001; graft: 56.4% vs 30.5%,
P < .001). In LD (54% vs 32%,
P < .001) and CAD (69% vs 55%,
P < .001) NEO reduced the incidence of AR and improved 8-year patient (LD: 81.8% vs 94.7%; CAD: 66.4 vs 79.9%,
P < .01) and graft survival (LD: 58.3 vs. 80%; CAD: 40.2% vs. 59.5%,
P < .01), compared to SIM. Overall 8-year graft survival was inferior among patients with increased 1-year creatinine values (≤1.5, 1.6–2.5 and >2.5 mg/dL) level (74% vs 63.9% vs 22.4%,
P < .001) or change in Cr (≤0.1, 0.2–0.4, >0.5 mg/dL) level (73.1% vs 61.9% vs 37.2%,
P < .001). In patients at the same level of graft function, those receiving NEO showed superior 8-year patient and graft survival compared with SIM.
Compared to SIM, NEO reduced the incidence of acute rejection and produced superior long-term patient and graft survival.]]></description><subject>Adult</subject><subject>Chemistry, Pharmaceutical</subject><subject>Cyclosporine - administration & dosage</subject><subject>Cyclosporine - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Emulsions</subject><subject>Female</subject><subject>Graft Survival - drug effects</subject><subject>Graft Survival - immunology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney Failure, Chronic - etiology</subject><subject>Kidney Failure, Chronic - surgery</subject><subject>Kidney Transplantation - immunology</subject><subject>Male</subject><subject>Retrospective Studies</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM2O1DAQhC0EYoeFV0AWB24JbjtxMtzQ8iuNxAXOVmK3Vx4Se7Cdlebt6dWMEEdObququlUfY29AtCBAvzu2NU-xnHKyiK6VQnStgFaM4xO2g3FQjdRSPWU7EqAB1fU37EUpR0F_2ann7AZ6UhTAjuVDivdNxbzyX8FFPPPL7mWKlaet2rRi4SHy01QDxlp4RovhIcR7nsLSzFNBx1Pma7A54botJaTIfco0UiTFwpPn9myXVE4ph4gv2TM_LQVfXd9b9vPzpx93X5vD9y_f7j4cGqsGXZt-1qPX1mnnod_bTiip96Pu-m6WeoJe6kHDIAZvrUdwekBJOb-f_V72yk3qlr297CVQvzcs1ayhWFyoGqatmAEGPfbQkfH9xUgNSsnozSmHdcpnA8I8EjdH8y9x80jcCDBEnMKvr1e2eSXtb_SKmAwfLwakrg8BsymWSFp0gVBW41L4nzt_AO2lnB8</recordid><startdate>20040301</startdate><enddate>20040301</enddate><creator>Medina-Pestana, J.O</creator><creator>Felipe, C.R</creator><creator>Park, S.I</creator><creator>Machado, P.G.P</creator><creator>Garcia, R</creator><creator>Spinelli, G</creator><creator>Silva, L.A</creator><creator>Santos, C.F</creator><creator>Tedesco-Silva, H</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040301</creationdate><title>Long-term kidney transplant outcomes in patients receiving oil-based or microemulsion formulations of cyclosporine</title><author>Medina-Pestana, J.O ; Felipe, C.R ; Park, S.I ; Machado, P.G.P ; Garcia, R ; Spinelli, G ; Silva, L.A ; Santos, C.F ; Tedesco-Silva, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-5b68f6cd6df159c40326986454b26a1526761707fccfe1d67e2376f9bf9253da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Chemistry, Pharmaceutical</topic><topic>Cyclosporine - administration & dosage</topic><topic>Cyclosporine - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Emulsions</topic><topic>Female</topic><topic>Graft Survival - drug effects</topic><topic>Graft Survival - immunology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney Failure, Chronic - etiology</topic><topic>Kidney Failure, Chronic - surgery</topic><topic>Kidney Transplantation - immunology</topic><topic>Male</topic><topic>Retrospective Studies</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Medina-Pestana, J.O</creatorcontrib><creatorcontrib>Felipe, C.R</creatorcontrib><creatorcontrib>Park, S.I</creatorcontrib><creatorcontrib>Machado, P.G.P</creatorcontrib><creatorcontrib>Garcia, R</creatorcontrib><creatorcontrib>Spinelli, G</creatorcontrib><creatorcontrib>Silva, L.A</creatorcontrib><creatorcontrib>Santos, C.F</creatorcontrib><creatorcontrib>Tedesco-Silva, H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Medina-Pestana, J.O</au><au>Felipe, C.R</au><au>Park, S.I</au><au>Machado, P.G.P</au><au>Garcia, R</au><au>Spinelli, G</au><au>Silva, L.A</au><au>Santos, C.F</au><au>Tedesco-Silva, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term kidney transplant outcomes in patients receiving oil-based or microemulsion formulations of cyclosporine</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2004-03-01</date><risdate>2004</risdate><volume>36</volume><issue>2</issue><spage>S74</spage><epage>S79</epage><pages>S74-S79</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><abstract><![CDATA[In the last 20 years long-term experience with cyclosporine use in kidney transplantation has increased, allowing a more precise identification of its benefits.
We performed a retrospective analysis of 1619 kidney transplants that received cyclosporine-based immunosuppressive therapy. Patients were divided into three groups (1) oil-based cyclosporine (SIM) with trough monitoring (GI,
n = 617); (2) microemulsion formulation (NEO) with trough monitoring (GII,
n = 962); and (3) NEO with C2 monitoring (GIII,
n = 40). Information was obtained on transplant demography; adjunctive immunosuppressive agent; living (LD) versus cadaveric (CAD) recipients; delayed graft function; any treated acute rejection; graft function at 3, 6, and 12 months, patient and graft survival, as well as causes of graft loss and death.
At 15 years follow-up, patient and graft survival were 67.5% and 41.6%, being superior, among LD versus CAD recipients (patient: 78.7% vs 57.7%,
P < .001; graft: 56.4% vs 30.5%,
P < .001). In LD (54% vs 32%,
P < .001) and CAD (69% vs 55%,
P < .001) NEO reduced the incidence of AR and improved 8-year patient (LD: 81.8% vs 94.7%; CAD: 66.4 vs 79.9%,
P < .01) and graft survival (LD: 58.3 vs. 80%; CAD: 40.2% vs. 59.5%,
P < .01), compared to SIM. Overall 8-year graft survival was inferior among patients with increased 1-year creatinine values (≤1.5, 1.6–2.5 and >2.5 mg/dL) level (74% vs 63.9% vs 22.4%,
P < .001) or change in Cr (≤0.1, 0.2–0.4, >0.5 mg/dL) level (73.1% vs 61.9% vs 37.2%,
P < .001). In patients at the same level of graft function, those receiving NEO showed superior 8-year patient and graft survival compared with SIM.
Compared to SIM, NEO reduced the incidence of acute rejection and produced superior long-term patient and graft survival.]]></abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>15041311</pmid><doi>10.1016/j.transproceed.2004.01.088</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1345 |
| ispartof | Transplantation proceedings, 2004-03, Vol.36 (2), p.S74-S79 |
| issn | 0041-1345 1873-2623 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71768514 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Chemistry, Pharmaceutical Cyclosporine - administration & dosage Cyclosporine - therapeutic use Drug Therapy, Combination Emulsions Female Graft Survival - drug effects Graft Survival - immunology Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - therapeutic use Kidney Failure, Chronic - etiology Kidney Failure, Chronic - surgery Kidney Transplantation - immunology Male Retrospective Studies Time Factors Treatment Outcome |
| title | Long-term kidney transplant outcomes in patients receiving oil-based or microemulsion formulations of cyclosporine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T15%3A21%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20kidney%20transplant%20outcomes%20in%20patients%20receiving%20oil-based%20or%20microemulsion%20formulations%20of%20cyclosporine&rft.jtitle=Transplantation%20proceedings&rft.au=Medina-Pestana,%20J.O&rft.date=2004-03-01&rft.volume=36&rft.issue=2&rft.spage=S74&rft.epage=S79&rft.pages=S74-S79&rft.issn=0041-1345&rft.eissn=1873-2623&rft_id=info:doi/10.1016/j.transproceed.2004.01.088&rft_dat=%3Cproquest_cross%3E71768514%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71768514&rft_id=info:pmid/15041311&rft_els_id=S0041134504001083&rfr_iscdi=true |